Growth factor inhibitors market to forecast to triple
The worldwide market for drugs that inhibit growth factors and angiogenesis will grow from less than US$4bn to more than $13bn in the next five years, according to a new study by Kalorama Information.
The worldwide market for drugs that inhibit growth factors and angiogenesis will grow from less than US$4bn to more than $13bn in the next five years, according to a new study by Kalorama Information.
According to the study, Growth Factor Inhibitors: Market Opportunities for a Growing Pipeline, much of the growth will occur in the rheumatology market, where growth factor inhibitors, such as Enbrel and Remicade, have already established themselves. The cancer market will evolve as a large segment as well, as the use of Iressa and Herceptin gains acceptance and additional indications and additional similar therapies enter the market.
Growth factor inhibitors may also turn out to be among the more cost-effective pharmaceutical therapeutics, according to the study. Because they target the source of the disease rather than eliminating its side effects, there is potential for them to be curative and, therefore, less expensive over the long term.
The study examines the current and future markets for growth factor inhibitor drugs in four therapy areas and across four geographic regions through to 2007. The study also examines the market share of current competitors, progress in research and development, and product, regulatory, and business trends.